Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
5.665(c) 5.58(c) 5.525(c) 5.415(c) 5.555 Last
122 180 108 445 113 511 154 672 107 849 Volume
+0.18% -1.50% -0.99% -1.99% +2.59% Change
More quotes
Financials
Sales 2020 96,4 M 109 M 109 M
Net income 2020 -23,9 M -27,0 M -27,0 M
Net cash position 2020 125 M 141 M 141 M
P/E ratio 2020 -7,52x
Yield 2020 -
Sales 2021 97,1 M 110 M 110 M
Net income 2021 -29,6 M -33,4 M -33,4 M
Net cash position 2021 86,4 M 97,6 M 97,6 M
P/E ratio 2021 -41,7x
Yield 2021 -
Capitalization 427 M 483 M 483 M
EV / Sales 2020 3,14x
EV / Sales 2021 3,51x
Nbr of Employees 235
Free-Float 75,3%
More Financials
Company
Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune system: the innate immunity. This approach receives validating partnerships with 2 main players of the biopharmacy:... 
More about the company
Surperformance© ratings of Innate Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on INNATE PHARMA
06/24INNATE PHARMA : U.S. Food and Drug Administration lifts partial clinical hold on..
GL
06/24U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TE..
GL
05/20Outcome Of Annual General Meeting Of May 19, 2020
GL
05/18INNATE PHARMA : Written questions to the Annual General Meeting
PU
05/14INNATE PHARMA : to Present New Efficacy Data For Monalizumab in Combination With..
GL
05/14Innate Pharma to Present New Efficacy Data for Monalizumab in Combination Wit..
GL
05/12INNATE PHARMA : Revenue for Q1
PU
05/12INNATE PHARMA : First Quarter 2020 Report
GL
05/12INNATE PHARMA : 1st quarter earnings
CO
05/07INNATE PHARMA : AGM convening Notice BALO
PU
04/28INNATE PHARMA : Financial resolutions tables
PU
04/28INNATE PHARMA : Text of resolutions to the 2020 AGM
PU
04/28INNATE PHARMA : Auditor's report PCAOB
PU
04/28INNATE PHARMA : Convening brochure to the 2020 AGM
PU
04/28INNATE PHARMA : Executive board report to the 2020 AGM
PU
More news
News in other languages on INNATE PHARMA
06/24EN DIRECT DES MARCHES : Atos, Europcar, Lagardère, Solvay, Innate, VMWare, Wi..
06/24INNATE PHARMA : bien orienté après la levée de suspension de la FDA sur l'étude ..
06/24La "Tech" enterre toujours le reste de la cote
06/24INNATE PHARMA : feu vert de la FDA à la reprise de Tellomak
06/24INNATE PHARMA : L'agence américaine du médicament lève la suspension partielle d..
More news
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 11,58 €
Last Close Price 5,42 €
Spread / Highest target 155%
Spread / Average Target 114%
Spread / Lowest Target 66,2%
EPS Revisions
Managers
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Pierre F. Dodion Chief Medical Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INNATE PHARMA-9.14%483
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344